Atopic Dermatitis Gene-Edited Cell Lines for Drug Discovery

Atopic dermatitis (AD) is a chronic inflammatory skin disease affecting approximately 15-20% of children and 1-3% of adults globally, according to the World Health Organization (WHO). The prevalence has increased 2-3 fold in industrialized nations over the past 30 years. AD significantly impacts quality of life, with severe pruritus, sleep disturbance, and increased risk of skin infections. The disease is also a major risk factor for the development of asthma and food allergies, a phenomenon known as the atopic march. The economic burden in the United States alone exceeds $5 billion annually, driven by healthcare visits, prescription costs, and lost productivity.

• • AD is an ideal model for studying gene-environment interactions, skin barrier dysfunction, and type 2 immune responses. Key research areas include:
• • Barrier integrity: filaggrin (FLG) loss-of-function mutations are the strongest genetic risk factor.
• • Immune dysregulation: Th2 cytokines (IL-4, IL-13, TSLP) drive inflammation.
• • Microbiome interactions: Staphylococcus aureus colonization exacerbates disease.
• • Public datasets: The NCBI Gene Expression Omnibus (GEO) contains hundreds of AD transcriptomic datasets, and the Human Cell Atlas includes skin cell atlases. Open questions remain about the role of specific keratinocyte subtypes, the contribution of sensory neurons to itch, and the mechanisms of chronicity.

AD pathogenesis involves a complex interplay of skin barrier dysfunction and immune activation. Key pathways include:

1. Epidermal Barrier Disruption

• • FLG mutations reduce natural moisturizing factors.
• • Increased transepidermal water loss (TEWL).
• • Allergen and microbial penetration.

2. Type 2 Immune Polarization

• • TSLP, IL-25, and IL-33 released by damaged keratinocytes.
• • Activation of dendritic cells and Th2 cells.
• • IL-4 and IL-13 promote IgE class switching and eosinophil recruitment.

3. JAK-STAT Signaling

• • IL-4/IL-13 binding to IL-4R activates JAK1/JAK3 and STAT6.
• • TSLP signals through JAK1/JAK2 and STAT5.
• • JAK inhibitors (e.g., upadacitinib) are effective therapeutics.

4. Neuroimmune Interactions

• • Sensory neurons release substance P and CGRP.
• • Mast cell activation and itch-scratch cycle.

Data from NCBI ClinVar, GWAS catalog, and meta-analyses (e.g., Paternoster et al., 2015).

Key signaling networks in AD:

• • JAK-STAT pathway:
• • IL-4/IL-13 -> IL-4R -> JAK1/JAK3 -> STAT6 -> Th2 gene expression.
• • TSLP -> TSLPR -> JAK1/JAK2 -> STAT5 -> dendritic cell activation.
• • NF-kB pathway:
• • Activated by TNF-alpha and IL-1 from keratinocytes.
• • Drives chemokine (CCL17, CCL22) and cytokine (IL-6, IL-8) production.
• • MAPK pathway:
• • ERK, JNK, p38 activated by stress and cytokines.
• • Regulates keratinocyte proliferation and differentiation.
• • Aryl hydrocarbon receptor (AhR) pathway:
• • Ligand-activated transcription factor.
• • Modulates barrier function and immune response.
• • Tapinarof (AhR agonist) is a topical therapeutic.

Organoid models: 3D skin equivalents (e.g., reconstructed human epidermis) with FLG knockdown recapitulate barrier defects. Organoids from AD patients maintain disease-specific features (e.g., reduced filaggrin, increased TSLP).

Common animal models for AD:

• • MC903-induced model: Topical MC903 (vitamin D analog) induces AD-like inflammation in mice.
• • Ovalbumin (OVA) challenge: Sensitization and epicutaneous challenge leads to Th2 inflammation.
• • Flaky tail mouse (ft/ft): Spontaneous FLG mutation, barrier defect, and dermatitis.
• • NC/Nga mouse: Spontaneous AD-like lesions under conventional housing.
• • Human skin xenograft: AD patient skin transplanted onto immunodeficient mice (PDX model).

CRISPR-engineered isogenic cell lines provide precise tools to study AD genetics. Examples:

• • FLG knockout in HaCaT or N/TERT-1 cells: Models barrier dysfunction; reduced filaggrin, increased TEWL in 3D cultures.
• • IL-4R gain-of-function knock-in (Q576R): Enhances STAT6 signaling, mimics hyper-responsive Th2 phenotype.
• • TSLP reporter lines: GFP or luciferase under TSLP promoter enables high-throughput screening for pathway modulators.
• • SPINK5 knockout: Models Netherton syndrome, severe barrier defect.

Commercially available, sequence-verified models accelerate research by reducing variability and enabling reproducible studies. These models are validated by Sanger sequencing and functional assays (e.g., filaggrin western blot, TEER measurement).

CRISPR knockout and knock-in lines validate causal roles of AD-associated genes. Examples:

• • FLG knockout in keratinocytes: Confirms that FLG loss alone reduces barrier function and increases allergen penetration.
• • IL-4R Q576R knock-in: Demonstrates enhanced IL-4 signaling and increased CCL17/CCL22 production.
• • TSLP knockout: Abolishes TSLP release, reducing dendritic cell activation in co-culture assays.

These models enable mechanistic studies in a controlled genetic background, avoiding confounding factors from patient heterogeneity.

Isogenic pairs (e.g., FLG wild-type vs. knockout) are used for:

• • Screening barrier-repair compounds: Measure TEWL, lipid composition, and tight junction proteins.
• • Testing JAK inhibitors: Compare IL-4-induced STAT6 phosphorylation in IL-4R wild-type vs. Q576R cells.
• • Resistance modeling: Chronic exposure to corticosteroids or calcineurin inhibitors can be modeled in gene-edited lines to study acquired resistance mechanisms.

CRISPR screens identify synthetic lethal interactions and novel biomarkers:

• • Genome-wide knockout screens in FLG-deficient cells: Identify genes essential for barrier function (e.g., CLDN1, OCLN).
• • Targeted screens for TSLP regulators: Discover novel modulators of the TSLP pathway, potential drug targets.
• • Secretome analysis of gene-edited lines: Identify biomarkers of disease activity (e.g., CCL17, periostin).